Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Cogent Biosciences Inc. (COGT)

NASDAQ: COGT · Pharmaceutical Preparations · Waltham, MA

Our rating: Neutral

Neutral reaffirmed at $31.64, moderate conviction, November 6, 2026.

Breaks if: Turn Cautious if the annualized FCF burn rate rises above $350M in any reported quarter over the next 12 months without a corresponding revenue line emerging, or if the stock declines more than 35% from today's price within that window in the absence of a disclosed recovery catalyst such as new financing or a strategic partnership. Turn Positive if Cogent reports a pivotal-trial success or NDA filing within the next 12 months alongside an explicitly confirmed cash runway of at least eight quarters.

Key figures

Market value$4.6B
Revenue, last 12 monthsn/a
Net income, last 12 months−$408M
Free cash flow, last 12 months−$326M
Price to earningsn/a
Free cash flow yield−7.0%
Dividend yield0.0%
Operating marginn/a
Return on equity−99.6%
Beta to the S&P 5001.70
Volatility, annualized95.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$-0.59−$81M
June 30, 2026n/an/a$-0.52−$78M
March 31, 2026n/an/a$-0.53−$87M
December 31, 2025n/an/a$-0.61−$80M
September 30, 2025n/an/a$-0.50−$64M
June 30, 2025n/an/a$-0.53−$55M
March 31, 2025n/an/a$-0.52−$67M
December 31, 2024n/an/a$-0.50−$61M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 36 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.